Akari Therapeutics (AKTX) Cash & Equivalents (2011 - 2026)

Akari Therapeutics' Cash & Equivalents history runs 16 years deep, the most recent figure standing at $2.8 million for Q1 2026.

• In Q1 2026, Cash & Equivalents rose 4.77% year-over-year to $2.8 million; the TTM figure through Mar 2026 stood at $2.8 million (up 4.77% YoY), while the FY2025 annual figure was $5.2 million, up 95.68% from the prior year.
• Cash & Equivalents came in at $2.8 million for Q1 2026 at Akari Therapeutics, down from $5.2 million in the prior quarter.
• In the past five years, Cash & Equivalents ranged from a high of $13.2 million in Q4 2022 to a low of $162567.0 in Q3 2025.
• A 5-year average of $4.8 million and a median of $3.3 million in 2023 frame the typical range for Cash & Equivalents.
• Across the five-year window, Cash & Equivalents slumped 99.91% in 2022 and soared 101.68% in 2025, its largest moves.
• Akari Therapeutics' Cash & Equivalents stood at $13.2 million in 2022, then slumped by 70.98% to $3.8 million in 2023, then sank by 30.85% to $2.7 million in 2024, then surged by 95.68% to $5.2 million in 2025, then plunged by 46.8% to $2.8 million in 2026.
• According to Business Quant data, Cash & Equivalents over the past three periods registered $2.8 million, $5.2 million, and $162567.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison